KEY TAKEAWAYS
- The study aimed to assess the effectiveness of 125I seed brachytherapy in managing NCPCR Cx post-EBRT.
- Researchers noticed the feasibility of 125I seed brachytherapy to treat NCPCR Cx as crucial prognostic indicators for improved efficacy.
Xuemin Di and the team were aimed to evaluate the effectiveness of 125I seed brachytherapy against non-central pelvic recurrent- cervical cancer(NCPCR Cx) localized in the non-central pelvic region following prior external beam radiotherapy(EBRT).
Researchers subjected a cohort of 32 patients (pts) with 41 lesions underwent treatment with 125I seed brachytherapy. The precise and guided implantation was performed which was assisted by CT and/or 3D-printed template images.
The procedure involved the precise implantation of seeds guided by CT and/or 3D-printed template images, administering a median dose of 100 Gy (range, 80-120 Gy). Subsequently, the study evaluated the local control rate (LCR) and survival rates in the pts.
They observed that when a median dose of 100 Gy (range, 80-120 Gy) was administered and LCR and survival rates were assessed in pts. With a median follow-up period of 48.52 months (range, 4-86 months), the LCR and survival rates at 1 and 2 years were 36% and 33% respectively, with a median survival time of 13.26 months.
No significant adverse events (AEs) were observed. Tumor diameter, tumor stage, and LCR were identified as independent factors that influenced survival as per the multivariate regression analysis. Further, receiver operating characteristic (ROC) curve analysis demonstrated that the area under the curve for tumor diameter and D90 were 0.765 and 0.542 respectively, with corresponding cut-off values of 5.3 cm and 108.5 Gy.
Overall, the results showed the feasibility of 125I seed brachytherapy in treating NCPCR Cx, post-EBRT, with tumor diameter < 5.3 cm and immediate postoperative D90 > 108.5 Gy correlating with enhanced efficacy.
The study did not receive any funding from the profit or not-for-profit sector.
Source: https://pubmed.ncbi.nlm.nih.gov/38849839/
Di X, Gao Z, Yu H, et al. (2024). “125I seed brachytherapy for non-central pelvic recurrence of cervical cancer after external beam radiotherapy.” Radiat Oncol. 2024 Jun 8;19(1):70. doi: 10.1186/s13014-024-02454-1. PMID: 38849839; PMCID: PMC11162001.
